110476-90-9

Upstream product

• 101411-57-8 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-2-<(2-oxopropoxy)methyl>-1,4-dihydropyridine 
• 90445-15-1 2-{[4-(2,3-dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridin-2-yl]methoxy}acetic acid 
• 41253-21-8 sodium triazole 
• 110464-40-9 2-<<<4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl>methoxy>methyl>-2-methyloxirane 
• 101411-65-8 1-<<4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyridin-2-yl>methoxy>-2-propyne 
• 288-88-0 1,2,4-Triazole 

Relevant academic research and scientific papers

Long-acting dihydropyridine calcium antagonists. 6. Structure-activity relationships around 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy) methyl]-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyridine

The preparation of 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy) methyl]-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrimidine (2) is described, and its potent calcium antagonist activity on rat aorta (IC50 = 4 x 10-9 M

2-oxygen containing heteroalkoxyalkyl dihydropyridine intermediates

1,4-Dihydropyridine anti-ischaemic and antihypertensive agent of the formula: STR1 or a pharmaceutically acceptable salt thereof, wherein R is 2-chlorophenyl, 2,3-dichlorophenyl or 2-chloro-3-trifluoromethylphenyl; R1 and R2 are each